Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(2):222-230 | DOI: 10.5507/bp.2016.013

Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs

Martin Hrubya, Khushboo Agrawalb, Olivia Policianovaa, Jiri Brusa, Jan Skopala, Pavel Sveca, Miroslav Otmarc, Petr Dzubakb, Petr Stepaneka, Marian Hajduchb
a Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic
b Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
c Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Fleming Sq. 2.166 10 Prague 6, Czech Republic

Background: The archetypal DNA methyltransferase inhibitors, 5-azacytidine (AZA) and 5-aza-2'-deoxycytidine (DAC) are potent antineoplastic agents used in the treatment of mainly, blood malignancies. However, the administration of these drugs is confounded by their hydrolytic lability which decreases plasma circulation time. Here, we describe a new biodegradable, polyanhydride formulation for drug delivery that circumvents this drawback.

Methods: Injectable/implantable polymeric microbeads containing dispersed microcrystals of hydrophilic AZA or DAC packed in a dry environment are protected from hydrolysis, until the hydrolytic zone reaches the core. Diclofenac is embedded into the formulation to decrease any local inflammation. The efficacy of the formulations was confirmed by monitoring the induced demethylation, and cytostatic/cytotoxic effects of continuous drug release from the time-course dissolution of the microbeads, using an in vitro developed cell based reporter system.

Results: Poly(sebaccic acid-co-1,4-cyclohexanedicarboxylic acid) containing 30 wt. % drug showed zero-order release (R2 = 0.984 for linear regression), and release rate of 10.0 %/h within the first 5 h, and subsequent slower release of the remaining drug, thus maintaining the level of drugs in the outer environment considerably longer than the typical plasma half-life of free azanucleosides. At lower concentrations, the differences between powder drug formulations and microbeads were very low or negligible, however, at higher concentrations, we discovered equivalent or increasing effects of the drugs loaded in microbeads.

Conclusions: The study provides evidence that microbead formulations of the hydrolytically labile azanucleoside drugs could prevent their chemical decomposition in aqueous solution, and effectively increase plasma circulation time.

Keywords: 5-azacitidine, 5-aza-2'-deoxycytidine, diclofenac, polyanhydride, microbeads

Received: July 23, 2015; Accepted: March 3, 2016; Prepublished online: March 21, 2016; Published: June 24, 2016  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Hruby, M., Agrawal, K., Policianova, O., Brus, J., Skopal, J., Svec, P., ... Hajduch, M. (2016). Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs. Biomedical papers160(2), 222-230. doi: 10.5507/bp.2016.013
Download citation

References

  1. Bryan J, Kantarjian H, Jabbour E. Decitabine for the treatment of acute myeloid leukemia. Expert Opin Orphan Drugs 2013;1(8):661-73. Go to original source...
  2. Gnyszka A, Jastrzebski Z, Flis S. DNA Methyltransferase Inhibitors and Their Emerging Role in Epigenetic Therapy of Cancer. Anticancer Res 2013;33(8):2989-96.
  3. Singh V, Sharma P, Capalash N. DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer. Curr Cancer Drug Targets 2013;13(4):379-99. Go to original source... Go to PubMed...
  4. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123(1):8-13. Go to original source... Go to PubMed...
  5. Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW, Sowers LC. Chemical Decomposition of 5-Aza-2 '-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass Spectrometry. Chem Res Toxicol 2009;22(6):1194-204. Go to original source... Go to PubMed...
  6. Kim JK, Kim HJ, Chung JY, Lee JH, Young SB, Kim YH. Natural and synthetic biomaterials for controlled drug delivery. Arch Pharm Res 2014;37(1):60-8. Go to original source... Go to PubMed...
  7. Doppalapudi S, Jain A, Khan W, Domb AJ. Biodegradable polymers-an overview. Polym Adv Technol 2014;25(5):427-35. Go to original source...
  8. Parent M, Nouvel C, Koerber M, Sapin A, Maincent P, Boudier A. PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release. J Control Release 2013;172(1):292-304. Go to original source... Go to PubMed...
  9. Lu CC, Wang XJ, Wu GL, Wang JJ, Wang YN, Gao H, Ma JB. An injectable and biodegradable hydrogel based on poly(alpha,beta-aspartic acid) derivatives for localized drug delivery. J Biomed Mater Res Part A 2014;102(3):628-38. Go to original source... Go to PubMed...
  10. Jain JP, Modi S, Domb AJ, Kumar N. Role of polyanhydrides as localized drug carriers. J Control Release 2005;103(3):541-63. Go to original source... Go to PubMed...
  11. Jain JP, Chitkara D, Kumar N. Polyanhydrides as localized drug delivery carrier: an update. Expert Opin Drug Deliv 2008;5(8):889-907. Go to original source... Go to PubMed...
  12. Pereira DY, Yip AT, Lee BS, Kamei DT. Modeling Mass Transfer from Carmustine-Loaded Polymeric Implants for Malignant Gliomas. J Lab Autom 2014;19(1):19-34. Go to original source... Go to PubMed...
  13. Casalini T, Perale G. Types of bioresorbable polymers for medical applications. In: Jenkins M, Stamboulis A, editors. Durability and Reliability of Medical Polymers. Cambridge: Woodhead Publ Ltd; 2002. p. 3-29. Go to original source...
  14. Teomim D, Domb AJ. Fatty acid terminated polyanhydrides. J Polym Sci, Part A: Polym Chem 1999;37(16):3337-44. Go to original source...
  15. Llinàs A, Burley JC, Box KJ, Glen RC, Goodman JM. Diclofenac solubility: Independent determination of the intrinsic solubility of three crystal forms. J Med Chem 2007;50(5):979-83. Go to original source... Go to PubMed...
  16. Kipper MJ, Shen E, Determan A, Narasimhan B. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. Biomaterials 2002;23(22):4405-12. Go to original source... Go to PubMed...
  17. Brus J. Heating of samples induced by fast magic-angle spinning. Solid State Nucl Magn Reson 2000;16(3):151-60. Go to original source... Go to PubMed...
  18. Okochi-Takada E, Ichimura S, Kaneda A, Sugimura T, Ushijima T. Establishment of a detection system for demethylating agents using an endogenous promoter CpG island. Mutat Res 2004;568(2):187-94. Go to original source... Go to PubMed...
  19. Policianova O, Brus J, Hruby M, Urbanova M, Zhigunov A, Kredatusova J, Kobera L. Structural Diversity of Solid Dispersions of Acetylsalicylic Acid As Seen by Solid-State NMR. Mol Pharmaceutics 2014;11(2):516-30. Go to original source... Go to PubMed...
  20. Urbanova M, Brus J, Sedenkova I, Policianova O, Kobera L. Characterization of solid polymer dispersions of active pharmaceutical ingredients by F-19 MAS NMR and factor analysis. Spectrochim Acta A Mol Biomol Spectrosc 2013;100:59-66. Go to original source... Go to PubMed...